



- (51) **International Patent Classification:**
C07D 473/00 (2006.01) *A61K 31/52* (2006.01)
- (21) **International Application Number:**
PCT/US2012/072103
- (22) **International Filing Date:**
28 December 2012 (28.12.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/582,550 3 January 2012 (03.01.2012) US
- (71) **Applicant:** CELLCEUTIX CORPORATION [US/US];
100 Cummings Center, Suite 151-B, Beverly, Massachu-
setts 01915 (US).
- (72) **Inventor:** MENON, Krishna; c/o Cellceutix Corporation,
100 Cummings Center, Suite 151-B, Beverly, Massachu-
setts 01915 (US).
- (74) **Agents:** RICHARDS, John et al.; Ladas & Parry LLP,
1040 Avenue of the Americas, New York, NY 10018 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

- (54) **Title:** CARBOCYCLIC NUCLEOSIDES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS



- (57) **Abstract:** Abstract of the Disclosure Disclosed are compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating inflammatory skin diseases.